4-((4-(2-butynyloxy)phenyl)sulfonyl)-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide,
apratastat,
TMI 005,
TMI-005,
TMI-1,
Apratastat,
TMI-005,
TMI-05,
TMI 005,
287405-51-0,
UNII-C6BZ5263BJ,
C6BZ5263BJ,
CHEMBL206815,
Apratastat [USAN:INN],
Apratastat (USAN/INN),
MLS006010301,
GTPL6482,
SCHEMBL2834310,
TMI005,
Apratastat, >=98% (HPLC),
BCPP000041,
BDBM50181008,
ZINC28571311,
API0013699,
DB13020,
compound 5h [PMID: 16426848],
4CA-0170,
SMR004701369,
D08859,
(3S)-N-Hydroxy-4-((4-((4-hydroxybut-2-ynyl)oxy)phenyl)sulfonyl)-2,2-dimethylthiomorpholine-3-carboxamide,
(3S)-N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide,
(S)-4-[4-(4-Hydroxy-but-2-ynyloxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide,
(S)-N-hydroxy-4-(4-(4-hydroxybut-2-ynyloxy)phenylsulfonyl)-2,2-dimethylthiomorpholine-3-carboxamide,
3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-,
Apratastat [USAN],
TMI-1,
D08NFK,
D0HG5M,
CID11452716,
Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst,
C484302,
Dual TACE/MMP-13 inhibitors (inflammation), Wyeth,
Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth,
4-((4-(2-butynyloxy)phenyl)sulfonyl)-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide,
N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethyl-thiomorpholine-3-carboxamide,